Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland